Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × tremelimumab × Lymphoid × Clear all

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5 Genitourinary 4 Head & Neck 3 Dermatologic 2 Plasma cell 1 Other solid neoplasm 1 Other neoplasm 1 Lymphoid 1 Gynecologic 1 Gastrointestinal 1 Endocrine 1 Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 226 Cyclophosphamide 140 fludarabine 68 Vincristine 65 Methotrexate 61 Doxorubicin 54 fludarabine phosphate 52 Lenalidomide 49 Etoposide 49 Cytarabine 47 Prednisone 46 Filgrastim 43 Dexamethasone 43 Bortezomib 38 Gemcitabine 34 Whole-Body Irradiation 33 Melphalan 32 Radiotherapy 30 ibrutinib 29 Granulocyte Colony-Stimulating Factor 29 Alemtuzumab 29 Tacrolimus 28 Mycophenolic Acid 28 Antilymphocyte Serum 28 obinutuzumab 27 Busulfan 27 Bendamustine Hydrochloride 27 Calcium Dobesilate 26 venetoclax 25 idelalisib 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02205333 2017-06-28

MEDI6469

MedImmune LLC

Phase 1/2 Terminated

48 enrolled 28 charts

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡